Press releases
Interim report July 1- September 30, 2024
24 October, 2024Summary of the first quarter (2024-07-01 – 2024-09-30) • Net sales amounted to MSEK 0,0 (0,0) • Operating profit/loss amounted to MSEK -1,3 (-1,1) • Earnings per share* SEK -0.06 […]
DexTech: Invitation to open Annual General Meeting and notice
26 September, 2024On Thursday, October 31, 2024, DexTech Medical AB (“DexTech”) will hold its Annual General Meeting. Subject to availability, non-shareholders are also welcome to participate without voting rights. At the meeting, […]
Dextech Medical AB Annual report 230701-240630
20 September, 2024Download the annual report below. Annual report DexTech Medical AB 230701-240630
Year-end report July 1, 2023 – June 30, 2024
30 August, 2024Summary of year-end report Fourth quarter (2024-04-01 – 2024-06-30) Net sales amounted to SEK 0.0 million (0.0) Operating profit amounted to SEK -1.6 million (-1.3) Earnings per share* SEK -0.07 […]
DexTech Medical announces continued positive results from myeloma study
12 August, 2024The Phase 1 study examines the effect of OsteoDex on patients with progressive multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. […]
Interim report July 1, 2023 – March 31, 2024
26 April, 2024Summary of the third quarter (2024-01-01 – 2024-03-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss amounted to MSEK -1,5 (-1,6) Earnings per share* SEK -0.08 (-0.08) Summary of […]
DexTech Medical announces new positive results from the myeloma study
15 April, 2024The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. […]
Half-year report July 1 – December 31, 2023
15 February, 2024Summary of the second quarter (2023-10-01 – 2023-12-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss amounted to MSEK -1,4 (-1,2) Earnings per share* SEK -0,06 (-0.06) * Before […]
DexTech Medical announces positive results from the myeloma study
23 January, 2024The first test results from patient 1 have been received and show a very strong effect on the marker of osteoclast activity (CTX). The baseline value for CTX decreases by […]
DexTech Medical informs about the myeloma study, the first patient is treated
13 December, 2023The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at Karolinska University Hospital in Huddinge. […]